CAGE Bio

CompanyUnited States

CAGE Bio develops one asset, in phase 3 (tofacitinib in rheumatoid arthritis). Mostly small molecule acting on JAK2, JAK1 and JAK3; based in the United States.

1
Asset
Furthest stage
Phase 3
Raised
$25M
3
Trials
6
Signals

Pipeline

1
  • tofacitinib

    Janus kinase (JAK) inhibitor that suppresses inflammatory cytokine signaling

    Phase 3, Small molecule, JAK2, JAK1, rheumatoid arthritis, ankylosing spondylitis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms5
  • Trials3
  • Funding rounds and grants3
  • People3
  • Signals14
  • Similar companies6

Intelligence